Nicole Ernstmann1, Lothar Weissbach2, Jan Herden3, Nicola Winter3, Lena Ansmann4. 1. Center for Health Communication and Health Services Research, Department of Psychosomatic Medicine and Psychotherapy, University Hospital Bonn, Germany, Bonn. 2. Stiftung Maennergesundheit, Berlin, Germany. 3. Department of Urology, University Hospital of Cologne, Cologne, Germany. 4. Institute for Medical Sociology, Health Services Research and Rehabilitation Science (IMVR), University of Cologne, Cologne, Germany.
Abstract
OBJECTIVES: To examine whether patient-physician communication is associated with health-related quality of life (HRQoL) in a sample of patients with localised prostate cancer undergoing radical prostatectomy (RP). PATIENTS AND METHODS: HAROW (Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting) is a prospective, observational study designed to collect data of the different treatment options for newly diagnosed patients with localised prostate cancer under real-life conditions. At 6-months intervals, clinical data (D'Amico risk categories, Charlson comorbidity index), aspects of patient-provider communication (standardised psychosocial-care instrument for patients' assessment of communication; Cologne Patient Questionnaire), and HRQoL (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) were assessed. Data were analysed by longitudinal multilevel analysis. RESULTS: Completed questionnaires for 1772 patients undergoing a RP were analysed over a 3-year follow-up period. Patients rated the patient-provider communication generally high with slight variations over the course of treatment (3.2-3.8). The HRQoL of the patients varied substantial over time and between the reported subscales (global HRQoL 71.1-77.2; physical functioning 89.1-92.1; role functioning 81.0-88.1; emotional functioning 74.4-84.0; cognitive functioning 84.3-87.7; social functioning (77.7-84.0). The longitudinal multilevel models showed significant associations between patient-provider communication in terms of devotion, support and shared decision-making, and functional aspects of HRQoL. CONCLUSION: Patient-provider communication is a valuable resource to support patients with prostate cancer coping with the disease and to improve their HRQoL. Future interventions should be designed especially for urologists to enhance their awareness for the importance of communication and the relationship with their patients with prostate cancer for treatment outcomes.
OBJECTIVES: To examine whether patient-physician communication is associated with health-related quality of life (HRQoL) in a sample of patients with localised prostate cancer undergoing radical prostatectomy (RP). PATIENTS AND METHODS: HAROW (Hormonal therapy, Active Surveillance, Radiation, Operation, Watchful Waiting) is a prospective, observational study designed to collect data of the different treatment options for newly diagnosed patients with localised prostate cancer under real-life conditions. At 6-months intervals, clinical data (D'Amico risk categories, Charlson comorbidity index), aspects of patient-provider communication (standardised psychosocial-care instrument for patients' assessment of communication; Cologne Patient Questionnaire), and HRQoL (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) were assessed. Data were analysed by longitudinal multilevel analysis. RESULTS: Completed questionnaires for 1772 patients undergoing a RP were analysed over a 3-year follow-up period. Patients rated the patient-provider communication generally high with slight variations over the course of treatment (3.2-3.8). The HRQoL of the patients varied substantial over time and between the reported subscales (global HRQoL 71.1-77.2; physical functioning 89.1-92.1; role functioning 81.0-88.1; emotional functioning 74.4-84.0; cognitive functioning 84.3-87.7; social functioning (77.7-84.0). The longitudinal multilevel models showed significant associations between patient-provider communication in terms of devotion, support and shared decision-making, and functional aspects of HRQoL. CONCLUSION:Patient-provider communication is a valuable resource to support patients with prostate cancer coping with the disease and to improve their HRQoL. Future interventions should be designed especially for urologists to enhance their awareness for the importance of communication and the relationship with their patients with prostate cancer for treatment outcomes.
Authors: Jens Klein; Daniel Lüdecke; Kerstin Hofreuter-Gätgens; Margit Fisch; Markus Graefen; Olaf von dem Knesebeck Journal: Qual Life Res Date: 2017-04-25 Impact factor: 4.147
Authors: Benjamin D Smith; Xiudong Lei; Kevin Diao; Ying Xu; Yu Shen; Grace L Smith; Sharon H Giordano; Sarah M DeSnyder; Kelly K Hunt; Mediget Teshome; Reshma Jagsi; Simona F Shaitelman; Susan K Peterson; Cameron W Swanick Journal: Ann Surg Oncol Date: 2020-01-08 Impact factor: 5.344
Authors: Brindha Pillay; Daniel Moon; Denny Meyer; Helen Crowe; Sarah Mann; Nicholas Howard; Addie Wootten; Mark Frydenberg Journal: Support Care Cancer Date: 2019-05-08 Impact factor: 3.603
Authors: Jana Jünger; Dominik Fugmann; Barbara Hinding; Ulrike Necknig; Stefan Bushuven; Stefanie Zschäbitz; Nancy Steiner; Peter Albers; Markus Giessing Journal: Urologie Date: 2022-10-07
Authors: Erin K Tagai; Suzanne M Miller; Alexander Kutikov; Michael A Diefenbach; Ronak A Gor; Tahseen Al-Saleem; David Y T Chen; Sara Fleszar; Gem Roy Journal: J Cancer Educ Date: 2019-06 Impact factor: 2.037
Authors: Lorena A Grondhuis Palacios; Esmée M Krouwel; Brenda L den Oudsten; Marjolein E M den Ouden; Gert Jan Kloens; Grethe van Duijn; Hein Putter; Rob C M Pelger; Henk W Elzevier Journal: Support Care Cancer Date: 2018-06-07 Impact factor: 3.603
Authors: Ruth E Ashton; Jonathan J Aning; Garry A Tew; Wendy A Robson; John M Saxton Journal: Support Care Cancer Date: 2021-01-23 Impact factor: 3.603
Authors: Young-Rock Hong; Sandhya Yadav; Ryan Suk; Ahmad Khanijahani; Daniel Erim; Kea Turner Journal: Cancer Med Date: 2021-05-07 Impact factor: 4.452